How to Reverse Type 2 Diabetes Naturally: The A1C, Insulin Resistance & Remission Protocol
Roy Taylor's twin-cycle hypothesis, in BellyProof voice. The biology, the trials, and the LION-modified protocol we use with diabetic clients.
Read the scienceMEDICAL DISCLAIMER
This guide provides educational information about type 2 diabetes reversal science. It is not medical advice, diagnosis, or treatment. If you take metformin, sulfonylureas, GLP-1 agonists, SGLT2 inhibitors, or insulin, do not modify your protocol without your physician. Hypoglycaemia from changing diet or fasting while on glucose-lowering medication can be life-threatening. Coordinate every change with your care team.
Three words, three outcomes
What 'reverse type 2 diabetes naturally' actually means
"Reverse type 2 diabetes naturally" is a loaded phrase. Three things matter, and most consumer guides conflate them.
The medical term
Remission
The only one with a standardised definition
HbA1c
6.5 percent, measured at least three months after stopping all glucose-lowering medication
Remission is the medical term and the only one with a standardised definition. The 2021 international consensus (Riddle et al., Diabetologia) requires HbA1c below 48 mmol/mol (6.5 percent) measured at least three months after stopping all glucose-lowering medication, sustained over time. The American Diabetes Association uses the same threshold. Diabetes UK publishes the same criteria.
If a guide says "reversed" without naming this threshold, it is not using the medical definition.
The consumer term
Reversal
Same outcome, plain language
Reversal is the consumer term for the same outcome. Pragmatically: your blood glucose is back in the non-diabetic range without drugs holding it there. Fasting glucose under 100 mg/dL, post-meal under 140 mg/dL, A1C under 5.7 percent if you want to be safely outside the prediabetic range as well.
Not available
Cure
The word type 2 diabetes does not get to use
Cure is the word type 2 diabetes does not get to use. The biology that drove your liver and pancreas into ectopic-fat dysfunction can return if the conditions return. Overeat past your personal fat threshold, regain the weight, and the same dysfunction follows.
The Newcastle group's 5-year DiRECT follow-up was honest about this: the people who held remission past 5 years were the ones who held the weight loss past 5 years.
The mechanism rewards consistency, not heroics.
Two recoveries, two speeds
Insulin sensitivity recovery
The upstream lever
Beta-cell function recovery
What makes it durable
Insulin sensitivity recovery is the upstream lever. Your cells start responding to insulin again before fasting glucose normalises. HOMA-IR (calculated from fasting glucose multiplied by fasting insulin) drops first; A1C drops over the next 3 months as the 90-day red-blood-cell turnover catches up.
If you measure A1C too early, the lever looks like it is not working. It is. You are reading the wrong number.
Beta-cell function recovery is what makes remission durable. Insulin sensitivity can come back fast (weeks). Pancreatic beta cells coming back online is slower (months). The 12-month and 2-year timelines in the next sections describe beta-cell mass, not insulin sensitivity.
This is why the early wins (A1C dropping 1 to 2 points in the first 3 to 6 months) feel fragile. Beta-cell capacity is still rebuilding underneath.
in structured trials
past 2 years
The honest framing. Remission is a real outcome, not a marketing claim. About 46 percent of people achieve it in structured trials with sustained 10 to 15 kg weight loss. About one-third hold it past 2 years. The lever that determines durability is not what protocol you start. It is what weight you maintain after the first year.
FREE AI TOOL See your BellyProof transformation before you start
Free AI body scan reads where you are now and projects you forward through fat loss and muscle building. No signup. 90 seconds.
Two loops, one bloodstream
The Twin Cycle how type 2 diabetes starts and stops
Roy Taylor (Newcastle University, awarded the Banting Lectureship in 2012 for this work) published the Twin Cycle Hypothesis of type 2 diabetes in the early 2010s and confirmed it through the Counterpoint study (2011), Counterbalance (2016), DiRECT (2018), and ReTUNE (2023). The hypothesis names two interlocking vicious cycles, both driven by ectopic fat. Fat stored in the wrong places.
Cycle 1: liver fat and insulin resistance
When you eat more energy than you burn, fat accumulates first in subcutaneous tissue (the fat you can pinch).
Past your personal threshold
Once that depot fills past your personal threshold, fat starts depositing in the liver. Fatty liver is not just a cosmetic problem. It is metabolically loud.
The liver stops listening
The liver responds to insulin's "stop making glucose" signal by ignoring it and producing glucose anyway.
Fasting blood sugar climbs
Fasting blood sugar climbs. The pancreas reads the high glucose and pumps more insulin.
High insulin, more triglyceride
High insulin tells the liver to make more triglyceride (de novo lipogenesis), which exports as VLDL.
The loop closes
The VLDL deposits some of itself back into the pancreas. Cycle 1 closes.
Cycle 2: pancreatic fat and beta-cell dysfunction
Pancreatic beta cells make insulin. They are not designed to sit in fat. When triglycerides accumulate inside the pancreatic islets, beta cells enter what Taylor's group calls de-differentiation.
They go dormant, they do not die
They essentially switch off the gene programs that make them beta cells (Al-Mrabeh et al., Cell Metabolism, 2020). They do not die. They go dormant.
Insulin secretion stops
They stop secreting insulin.
Glucose climbs further
Glucose climbs further.
The survivors join them
The remaining functional beta cells overwork to compensate, accumulate more fat, and join the dormant pool. Cycle 2 closes.
The clinical picture you experience as "type 2 diabetes" is the steady-state output of these two cycles running in parallel and reinforcing each other through the bloodstream. The liver is making more glucose than it should. The pancreas is secreting less insulin than it should. The cells that do see insulin have stopped responding to it the way they used to.
Why this matters for reversal.
The cycles are reversible if you reverse the input. Remove the energy surplus that is keeping ectopic fat parked in the liver and pancreas, and the fat clears in a specific sequence.
Liver fat clears
Pancreatic fat clears
Beta cells re-differentiate
Insulin sensitivity recovers
Liver fat goes first because the liver mobilises triglyceride aggressively when its own VLDL export pathway is no longer overwhelmed. Pancreatic fat goes next because pancreatic islets clear once their VLDL supply line dries up. Beta cells re-differentiate. They switch their gene programs back on and start secreting insulin again. Insulin sensitivity recovers in liver and muscle. The cycles reverse.
Roy Taylor's twin cycle is the diabetes-shaped expression of the same portal-vein biology that drives stubborn-belly-fat reduction.
This is exactly the same biology BellyProof has been working with on the visceral-fat side of the story (see our deep-dive on hidden belly fat and the lipolysis to beta-oxidation pathway). The portal vein drains visceral fat directly to the liver. What you mobilise from the abdominal depot lands in the liver first, and what the liver clears, the pancreas clears next.
From the coaching record
In our work with diabetic clients, this is the framing that changes the conversation. Clients hear "lose weight to reverse diabetes" as advice, and tune out. They hear "clear liver fat in 7 days, clear pancreatic fat in 8 weeks, restart insulin secretion" as a mechanism, and ask the right next question: how do I do that, and how will I know it is working? That is the rest of this guide.
The threshold is yours, not the chart's
The personal fat threshold (and why lean type 2 is real)
A common assumption in T2 reversal coverage is that diabetes happens to overweight people. The Twin Cycle Hypothesis says something more precise. Diabetes happens to people who have crossed their personal fat threshold, and that threshold is set individually, not by a universal BMI cutoff.
Where the line actually falls
Official "healthy weight" range An individual's own threshold
What this means: there is no universal "you are safe below this weight." Each person has a fat-storage capacity in subcutaneous tissue, set by genetics, sex, ethnicity, and probably early-life nutrition. When you exceed your capacity, fat starts depositing ectopically. In the liver, in the pancreas, around the heart, between the muscle fibres. Regardless of what the scale says. Some people exceed their threshold at BMI 35. Some do at BMI 23.
The evidence
ReTUNE, 2023 (Clinical Science) , "non-overweight type 2 diabetes"
of body mass
Roy Taylor's group published the ReTUNE study in 2023 (Clinical Science) on what they called "non-overweight type 2 diabetes." Participants had BMIs between 21 and 27. Most of them inside the official "healthy weight" range. They had type 2 diabetes anyway. The intervention was the same Newcastle Diet protocol used in DiRECT, scaled to a smaller starting weight. Average weight loss was 6.5 percent of body mass. 70 percent achieved remission. Same mechanism, lower starting weight, same outcome. The biology did not care about the BMI category.
The TOFI pattern is the personal fat threshold by another name.
TOFI (Thin on the Outside, Fat on the Inside) is the metabolic phenotype where subcutaneous storage is at capacity, ectopic deposition is active, and visceral fat is accumulating around the organs while limbs and face stay lean. We have covered it in detail at visceral fat vs subcutaneous fat and depot-selective fat retention. Lean type 2 diabetes is TOFI plus enough years and dietary load for the liver and pancreas to start failing.
Practical implications for the lean prediabetic or newly-diagnosed reader:
You still need to lose weight to reverse it.
ReTUNE used the same protocol that worked for higher-BMI participants. The percentage matters more than the absolute number. 6.5 percent body mass for a 60 kg person is around 4 kg. That is the threshold to cross.
Where the fat comes off matters more than how much.
Visceral and ectopic fat is the metabolically loud fat. Subcutaneous fat is metabolically quiet. The protocols that prioritise visceral mobilisation (LION-protocol fasted training, low-carb cycling, the BellyProof signature methodology) clear ectopic depots faster than steady-state caloric restriction does.
Weight maintenance is what holds the remission.
Same as for higher-BMI participants. ReTUNE's follow-up tracked the same pattern as DiRECT. Sustained remission tracked sustained weight maintenance.
The lean-T2 reader who has been told "you are not overweight, this is not about diet" by a clinician who did not read ReTUNE has been given outdated information. The mechanism is the same. The threshold is personal, not statistical.
Four repairs, four different clocks
Sequential reversal 7 days to 2 years
The Twin Cycle reverses in a specific order, set by the biology. Knowing the order tells you which marker to watch at which timepoint and stops you from quitting in week 4 because A1C has not moved yet.
Liver fat clears (~30%)
Moves 1stDay 0 to Day 7: liver fat clears. The liver is the most metabolically responsive organ in the body. When dietary energy drops below maintenance, the liver mobilises stored triglyceride aggressively. By mechanism, glucagon and adrenaline activate hepatic lipase, lipid droplets shrink, and VLDL export drops because there is less substrate to package. Lim et al. (Diabetologia, 2011) measured this directly: 30 percent reduction in liver fat by day 7 of the Newcastle Diet. Marker that moves first: fasting blood glucose. Many participants see fasting glucose drop by 30 to 50 mg/dL within the first week. This is liver fat clearing, not pancreatic recovery.
Week 4 , where most people quit
A1C has not moved yet. It is not supposed to have. The biology is already two repairs deep; the marker you are checking runs three months behind it.
Pancreatic fat clears, beta cells re-differentiate
Moves 2ndWeek 1 to Week 8: pancreatic fat clears, beta cells re-differentiate. Once liver fat is normalising, pancreatic VLDL supply drops. Pancreatic islets stop accumulating triglyceride and start clearing what is already there. Steven et al. (Diabetes Care, 2016) and Al-Mrabeh et al. (Cell Metabolism, 2020) both measured pancreatic triacylglycerol normalising by week 8 in DiRECT-protocol participants. Beta cells re-differentiate. They switch their insulin-secretion gene programs back on. Marker that moves second: first-phase insulin response, the rapid insulin spike when glucose enters the blood. Most clinicians will not measure this. You will feel it as post-meal glucose readings smoothing out.
A1C reflects month-3 glucose
Moves 3rdMonth 2 to Month 12: beta-cell mass recovery. Beta cells that were dormant do not only re-differentiate. Over months, the population grows. Al-Mrabeh and colleagues (Cell Metabolism, 2020) tracked DiRECT participants out to 24 months and showed pancreatic shape and beta-cell mass continuing to recover through year one and into year two. Marker that moves third: HbA1c. The 90-day red-blood-cell turnover means A1C lags glucose by approximately 3 months. By month 6, A1C reflects what fasting glucose was doing at month 3.
Beta-cell mass recovers
Moves 4thYear 1 to Year 2: pancreatic morphology normalises. Long-term DiRECT imaging showed the pancreas physically reshaping toward normal size and contour over 24 months in participants who maintained their weight loss. Marker that moves fourth: durability. Staying off medication while maintaining HbA1c below 6.5 percent.
Pancreatic shape normalises
DurabilityHolds if weight holds
The conditionYear 2 plus: durability is weight-maintenance dependent. The Newcastle group's long-term DiRECT follow-up showed the majority of remitters who held the weight loss held the remission. Those who regained more than approximately 6 kg above their post-intervention weight largely returned to diabetes. Same biology in reverse. Fat repacking into liver and pancreas in the same order it cleared.
The honest takeaway
If you measure A1C at week 4 and it has not moved, the protocol is still working. The mechanism upstream of A1C, liver fat clearance, pancreatic fat clearance, beta-cell recovery, is happening on its own clock. Do not quit a 12-month protocol on a 4-week marker.
Five levers, in priority order
How to lower A1C naturally the 5-lever protocol
How to lower A1C naturally is a question with a precise answer if you remember what A1C measures. It is the 90-day average of how much glucose has been parked in your blood, glycating the haemoglobin inside your red blood cells. Lower the glucose, you lower the A1C. But the lever that lowers glucose is insulin sensitivity recovery in the liver and muscle, and beta-cell capacity recovery in the pancreas. Everything below is upstream of glucose. Move them in the right order and A1C follows.The 5-lever protocol, in priority order:
Lever 1: Energy deficit sufficient to clear ectopic fat
Reversal phaseThis is the upstream lever. The Counterpoint study used 600 to 800 kcal per day for 8 weeks under medical supervision. The DiRECT trial used 825 to 853 kcal per day liquid formula for 12 to 20 weeks under physician supervision. Both achieved approximately 15 kg weight loss and approximately 46 percent remission. These are clinical-trial protocols, not daily-habit recommendations. Very-low-energy diets require medical supervision and are not sustainable as a lifestyle. Past the reversal phase, the levers below take over. Without sufficient initial deficit, ectopic fat does not clear, and the Twin Cycle keeps running.
Lever 2: Low-carb cycling, not chronic low-carb
MaintenanceSustained low-carbohydrate diets help, but the bigger lever is insulin-load timing. Insulin is the master switch on the Twin Cycle. High insulin tells the liver to store fat, blocks lipolysis, and keeps ectopic depots loading. Low-carb cycling, heavier carb intake on training days, lower carb intake on rest days, preserves the insulin-sensitivity gains from training while keeping average insulin load low. See our carb cycling guide for the full protocol. The carb count itself is less important than the timing relative to insulin sensitivity.
Lever 3: LION protocol intermittent fasting
MaintenanceExtending the overnight fast to 16 to 18 hours drops average insulin to baseline for a meaningful fraction of every 24-hour cycle. With insulin low, lipolysis runs (HSL and ATGL active), CPT-1 is unblocked (fatty acids enter mitochondria for beta-oxidation), and alpha-2 receptor inhibition lifts on stubborn depots. The LION protocol layers fasted morning training on top. Catecholamine spike during the window of lowest insulin equals maximum lipolytic signal. For diabetics, intermittent fasting requires safety modifications. Coordinate with your physician first if you are on metformin, sulfonylureas, or any insulin. The dedicated section below names the guardrails.
Lever 4: Resistance training and walking, minimum 150 min per week
Foundationwith lifestyle 31%Metformin,
same trial
Resistance training drives GLUT4 translocation in skeletal muscle. Muscle cells pull glucose out of the blood without needing insulin. Walking drives mitochondrial density and raises basal insulin sensitivity. The Diabetes Prevention Program (Knowler et al., NEJM, 2002) showed lifestyle intervention with 150 minutes per week activity reduced T2 conversion by 58 percent in prediabetic participants. Better than metformin (31 percent) at any age, and dramatically better in participants over 60. If you have neuropathy, see the neuropathy reversal page for foot-safe modifications.
Lever 5: Sleep architecture and stress regulation
Foundationafter ONE night -20%Peripheral
glucose disposal
Cortisol is the underrated lever. Donga and colleagues (2010) measured what one night of 4-hour sleep does to glucose metabolism the next morning under hyperinsulinemic-euglycemic clamp in healthy adults. Hepatic insulin sensitivity dropped (endogenous glucose production rose ~22 percent during the clamp) and peripheral glucose disposal fell ~20 percent. Both pathways were affected, in different tissues, after a single night of restriction (Donga et al., JCEM, 2010). Chronic sleep restriction stacks the same insult day-on-day. Stress-driven cortisol elevation does the same thing through a different pathway: it promotes hepatic gluconeogenesis and blunts insulin signalling. Without sleep and stress regulation, the first four levers underperform. See the sleep, muscle, fat loss and longevity guide for the full sleep-glucose protocol.
Reversal phaseLever 1
The order matters. Lever 1 (deficit) is the dominant variable for the reversal phase.
Post-reversalLevers 2 to 3
Levers 2 to 3 (carb cycling and LION) are the maintenance protocol post-reversal. Skip Lever 1 and the others underdeliver.
Holds past year oneLevers 4 to 5
Levers 4 to 5 (training and sleep) are the foundation that holds the remission past year one. Skip Levers 4 to 5 and the remission will not last past 2 to 3 years even if you nail the first three.
From the coaching record
In our work with diabetic clients, the question we ask first is which lever they are missing, not which one to add. Most clients arrive doing two of the five well and three poorly. The 12-month protocol is about closing the gaps in priority order, not stacking new interventions on top of broken foundations.
The next sections walk how to reverse insulin resistance specifically, what the DiRECT, Counterpoint, and ReTUNE trials measured side-by-side, and how to run the LION protocol if you are on glucose-lowering medication.
Three tissues, three locks, one key
How to reverse insulin resistance the biology and the levers
How to reverse insulin resistance is the same question as how to reverse type 2 diabetes, asked one step upstream. Insulin resistance is what drives high glucose. Type 2 diabetes is what high glucose plus failing beta cells looks like clinically. Reverse insulin resistance early enough and the diabetes never fully establishes. Reverse it after diabetes is established and you are running the Twin Cycle backward.Insulin resistance is not one thing. It is three different things in three different tissues, and each responds to a different lever:
Three failures, one bloodstream
Hepatic insulin resistance
Hepatic insulin resistance means the liver has stopped responding to insulin's "stop making glucose" signal. The liver makes glucose anyway (gluconeogenesis), and fasting blood glucose climbs overnight. The lever: clear liver fat. This is the fastest tissue to respond. Within 7 days of sufficient energy deficit, fasting glucose typically drops 30 to 50 mg/dL.
Skeletal-muscle insulin resistance
Skeletal-muscle insulin resistance means muscle cells have stopped pulling glucose out of the blood efficiently when insulin signals "glucose available, take it up." Glucose backs up into circulation.
Adipose-tissue insulin resistance
Adipose-tissue insulin resistance means fat cells have stopped responding to insulin's "store fat, do not release fat" signal correctly. Lipolysis stays active even after meals (instead of switching off the way it should), free fatty acids stay elevated in circulation, and those fatty acids feed back into the liver as substrate for VLDL export.
Insulin's triple block (and how to lift it).
High insulin shuts down fat mobilisation through three parallel mechanisms. Low insulin lifts all three.
Hormone-sensitive lipase
Block 1: insulin inhibits hormone-sensitive lipase (HSL), the enzyme that cleaves stored triglyceride into free fatty acids. No HSL activity equals no lipolysis equals no fat leaving storage.
The mitochondrial gate
Block 2: insulin inhibits CPT-1 (carnitine palmitoyltransferase 1), the gatekeeper that escorts fatty acids into mitochondria for beta-oxidation. Even if fatty acids are released, they cannot be burned.
Alpha-2 on the stubborn depots
Block 3: insulin upregulates alpha-2 adrenergic receptors on stubborn fat depots, including visceral and lower-belly storage. Alpha-2 receptors actively suppress lipolysis. The same depots already biased toward alpha-2 activity get more of it under high insulin.
Overnight fast extension, low-carb cycling, fasted training
Drop insulin to baseline (overnight fast extension, low-carb cycling, fasted training) and all three blocks lift. HSL activates. CPT-1 opens. Alpha-2 inhibition fades. Visceral fat starts mobilising through the portal vein toward the liver, which is exactly the route Roy Taylor's mechanism predicts the fat clearing during the early reversal phase.
Reduce insulin enough, long enough, often enough, that visceral fat can flow out faster than it flows in.This is why visceral fat insulin resistance sits at the centre of the BellyProof framing. The portal vein drains visceral fat directly to the liver before any other circulation. What you mobilise from the abdominal depot lands in the liver first. Whether you are reversing diabetes (Roy Taylor's frame) or attacking stubborn belly fat (BellyProof's frame), the upstream lever is the same: reduce insulin enough, long enough, often enough, that visceral fat can flow out faster than it flows in. Cleaner liver follows. Cleaner pancreas follows. Insulin sensitivity recovers in muscle and adipose. The diabetes recedes.
What to actually track
The practical implication for measurement: do not chase A1C alone. Track HOMA-IR (calculated from fasting glucose multiplied by fasting insulin, divided by 405). HOMA-IR is the upstream marker that moves first. A1C is a 90-day downstream lagging indicator. If HOMA-IR is dropping while A1C has not moved yet, the protocol is working. If HOMA-IR has plateaued for 8 weeks while A1C continues to drift, you have hit the limit of insulin sensitivity recovery and need to lean harder on beta-cell-recovery mechanisms (energy deficit, sustained weight loss, pancreatic fat clearance).
You can keep reading. Or you can see what this looks like in real bodies.
Same mechanism you just read about. Different bodies. Same outcome.
The evidence base
DiRECT, Counterpoint, ReTUNE what the trials actually measured
Three trials anchor the type 2 diabetes reversal evidence base. Each tested a piece of the twin-cycle hypothesis. Together they describe the boundary conditions of remission: who responds, how much weight loss is needed, how long the response lasts, and what BMI ranges the mechanism works in.
What the four-trial arc says.
Counterpoint (2011) proved the mechanism: 8 weeks of energy deficit cleared liver and pancreatic fat in a small cohort. Counterbalance (2016) showed responders held remission at 6 months when weight stayed off. DiRECT (2018, n=298) scaled the protocol to primary-care delivery and produced the headline 46 percent remission rate at 1 year. ReTUNE (2023) extended the mechanism to lean type 2 (BMI 21-27) and confirmed the personal fat threshold concept: 70 percent remission with only 6.5 percent body-mass loss when participants crossed their own threshold.
The 5-year follow-up
11% Still in remissionThe durability honest-stop.
The 5-year DiRECT follow-up (Lean et al., 2024) is the durability honest-stop. Approximately 11 percent of original intervention participants (roughly 13 of 146 randomised) were still in remission at 5 years. The decline tracked weight regain. The participants who held the weight loss past 5 years held the remission past 5 years. The participants who regained more than approximately 6 kg above their post-intervention nadir largely returned to diabetes through exactly the mechanism the twin-cycle predicts in reverse: fat repacking into liver and pancreas in the same order it cleared.
Lean et al., Lancet Diabetes & Endocrinology 2024, PMID 38423026
This is the framing missing from most consumer reversal coverage. Remission is achievable for roughly half of participants in structured trials with 10 to 15 kg weight loss. Durability is weight-maintenance dependent, not protocol dependent.
The protocol that gets you to remission is not the protocol that holds you in remission.
The reversal arc
Trial-phase VLCD (clinical supervision, 8 to 12 weeks) is for the reversal arc.
The maintenance arc
Sustainable lifestyle (insulin-load timing, training, sleep) is for the maintenance arc that determines the 5-year outcome.
Remission arrivals
Status board- ISLETBeta-cell recovery, measuredHuman evidence the cells are suppressed, not deadLandedPublished Oct 2025
Published in Science Advances in October 2025. Islets taken from 21 people with type 2 diabetes were placed in a normal glucose environment, and about 60% significantly recovered their glucose responsiveness within three days.
- How it works
- Over 400 genes shifted once the sugar load was removed: insulin-secretion genes switched back up, inflammatory signalling switched down. The cells were being suppressed by the environment they sat in rather than being permanently broken.
- What it would mean
- This is the mechanism the whole reversal argument rests on, shown directly in human tissue rather than inferred from weight-loss trials. Three days is also strikingly fast.
- What has to happen next
- Human trials. This was donor tissue in a dish plus mouse work, not people. A drug-repurposing arm flagged some existing anti-inflammatory drugs, but none of that has been tested in a person with diabetes.
- DUR-4v8The duration limit, quantifiedWhy acting early matters more than trying harderLandedPublished Feb 2026
47 people on a very low calorie diet with diabetes medication stopped. Those diagnosed within four years reached remission 82% of the time. Those diagnosed eight or more years ago, 50%. They lost the same amount of weight.
- How it works
- Weight loss empties fat out of the liver and pancreas either way. What differs is how much insulin-producing capacity survived the years of pressure before the intervention started.
- What it would mean
- Effort does not substitute for time. Two people can do the identical programme, lose identical weight, and get different outcomes because of when they started. It is the strongest argument the page can make for acting now.
- What has to happen next
- Larger confirmation. 47 people is small, and this study used a looser fasting-glucose definition of remission rather than the standard one.
- GLP-REMGLP-1 drugs and remissionWhat these drugs actually deliverOn trackEvidence in hand
Across 14,141 people starting GLP-1 drugs, only 5.8% reached the strict definition of remission, normal blood sugar with all diabetes drugs stopped. Median duration was five to six months. Loosen the definition to allow ongoing medication and the figure rises to 18.3%.
- How it works
- These drugs control glucose and drive weight loss while they are being taken. They do not appear to restore the underlying capacity in a way that persists once they stop.
- What it would mean
- They are genuinely good at what they do, including a 12 to 16% reduction in microvascular complications. But control while medicated is a different thing from remission, and the numbers are not close. Diet-driven remission in the same window ran at 36% at two years.
- What has to happen next
- Longer follow-up. No dual or triple agonist has published a drug-free remission endpoint at all.
- ORFOOrforglipron (Foundayo)First oral GLP-1 with no timing rulesLandedApproved for weight, not diabetes
FDA approved in 2026 for weight management in obesity or overweight with a related condition. A separate type 2 diabetes application is planned but has not been approved.
- How it works
- A small-molecule GLP-1 receptor agonist that works as a tablet, with no food, water or timing restrictions. Existing oral options require an empty stomach and a waiting period.
- What it would mean
- The convenience change is real for anyone who will not inject. Read the label carefully though: it is approved to treat weight, not diabetes, and it has no remission data behind it.
- What has to happen next
- The diabetes submission, on the ACHIEVE trial programme. Until that clears, using it for diabetes is off-label.
- REM-DEFThe remission concept itselfSenior diabetologists pushing backDelayedOpen argument
A 2025 paper in Lancet Diabetes and Endocrinology argues remission is a temporary state for most people, and that no conclusive evidence shows drug-free normal blood sugar is better than the same numbers achieved with medication.
- How it works
- The 2021 consensus defines remission as HbA1c under 6.5% at least three months after stopping medication. The critique is that this sets up a binary that most people cross and then cross back.
- What it would mean
- Worth taking seriously rather than dismissing. The strongest reply is that drug-free normal glucose removes cost, side effects and dependence on continued access, and that the trial evidence showed about half the serious hospitalisations. The claim that it is biologically superior at the same glucose level is not proven.
- What has to happen next
- A trial designed to compare the two states directly. None exists, which is precisely the gap the critique points at.
- DIRECT5DiRECT long-term dataHow durable diet-driven remission isLanded5-year data, no newer
At five years, 34% of the extension group were in remission against 12% of comparators, and 62% were off glucose-lowering medication against 30%. Roughly a quarter of those in remission at two years were still in remission at five.
- How it works
- Sustained weight loss keeps fat out of the liver and pancreas. Relapse tracks weight regain more than anything else.
- What it would mean
- This is the honest durability picture. Remission is real and can last years, and it is also lost by most people who regain the weight. Both halves belong on the page.
- What has to happen next
- Nothing further is published. There is no eight-year follow-up, so five years is the current limit of what anyone knows.
Fasting on medication
The LION protocol for diabetics intermittent fasting with safety modifications
Critical safety note
Critical safety note. If you take metformin, sulfonylureas (gliclazide, glipizide, glimepiride), GLP-1 agonists (semaglutide, liraglutide, tirzepatide), SGLT2 inhibitors, or any insulin, do not start intermittent fasting without your physician. Sulfonylureas and insulin in particular create real hypoglycaemia risk during fasting windows. Sulfonylurea-induced hypoglycaemia can be prolonged and severe. The protocol below is what we run with clients after physician sign-off. It is not a do-it-yourself path on glucose-lowering medication.
One day on the protocol
The LION protocol is BellyProof's intermittent-fasting framework: extended overnight fast, fasted morning training inside the lowest-insulin window, single eating window in the late afternoon or evening with the largest meal at the end of training. For non-diabetic users, it works through the insulin-triple-block mechanism described above: low average insulin opens lipolysis, beta-oxidation, and adrenergic mobilisation simultaneously.
For diabetic users, the same biology applies, but three modifications are non-negotiable.
Modification 1: medication coordination first, fasting window second.
Metformin is generally compatible with extended fasting and has data suggesting it amplifies fasting-induced AMPK activation. Sulfonylureas and short-acting insulin must be timed to match the eating window: dosing during a fasted state risks hypoglycaemia 2 to 6 hours later. SGLT2 inhibitors carry euglycaemic ketoacidosis risk during prolonged fasts and are usually paused for the reversal phase. GLP-1 agonists already produce satiety and reduced food intake; layering an extended fast can make the eating window too short for adequate protein. Your physician decides which medications change, in what order. We coordinate the fasting window around their decisions.
Modification 2: hypoglycaemia guardrails during the fast.
Fingerstick glucose check on waking. If fasting glucose is below 70 mg/dL, break the fast with a small protein-focused snack and reassess medication timing with your clinician. Carry fast-acting glucose (15 g dextrose tablet, fruit juice, glucose gel) during the fasting window for any reading below 70 mg/dL or symptoms (sweating, tremor, confusion, palpitations).
The 15-15 rule
The 15-15 rule applies: 15 g of fast-acting carbs, recheck in 15 minutes, repeat if still below 70.
Modification 3: gradual extension, not abrupt window.
Most clients without diabetes can move to a 16-hour fasting window in the first week. Diabetic clients on glucose-lowering medication move at half speed. Week 1: 12-hour overnight fast (most people already do this naturally). Week 2: 13 hours. Add an hour per week, with daily fasting glucose monitoring, until 16 to 18 hours feels stable and predictable. If overnight glucose rises (dawn phenomenon worsening) or daytime glucose becomes erratic, contract the window and stabilise before extending.
What the LION protocol does for type 2 diabetes specifically.
Lowering average insulin over the 24-hour cycle does three things relevant to reversal. First, it gives the liver more hours per day with low insulin, which is when hepatic VLDL export quiets and liver fat starts mobilising preferentially. Second, it lifts the alpha-2 receptor inhibition on visceral fat, which routes more mobilised fatty acids through the portal vein toward the liver during the morning training window. Third, it pairs catecholamine spike (from fasted training) with the lowest-insulin moment of the 24-hour cycle, which is the largest lipolytic-signal-to-insulin-block ratio physiologically achievable without pharmacological intervention. Stack this for 12 to 16 weeks alongside a moderate energy deficit and the twin-cycle mechanism reverses on roughly the timeline Roy Taylor's group documented.
From the coaching record
In our work with diabetic clients on metformin, we have found the LION-modified protocol typically takes 6 to 8 weeks to feel stable, after which fasting glucose readings smooth out and the 16-hour window holds without symptomatic hypoglycaemia. Clients on sulfonylureas or insulin take longer, usually move slower, and require closer physician coordination, sometimes including medication reduction during the protocol's ramp-up phase. The clients who try to compress the timeline rarely make it past week 3.The clients who run the gradual ramp tend to hold the protocol past year one, which is the lever that determines durability.
What high glucose leaves behind
Glycation, AGEs, and microvascular damage why uncontrolled glucose costs you nerves and arteries
HbA1c is named for what it measures. The 'A1c' fraction of haemoglobin is the slow, non-enzymatic glycation product of glucose attaching to haemoglobin's beta chain over the lifespan of the red blood cell. The same glycation reaction is happening to every other long-lived protein in your body, all the time, in proportion to your average blood glucose.
Collagen in artery walls.
Arteries
Lens crystallins in your eyes.
Eyes
Basement-membrane proteins around capillaries.
Capillaries
Myelin sheaths around peripheral nerves.
Nerves
The slower the protein turnover, the more glycation accumulates.
Glycation is reversible at the rate of protein turnover.
Over years, glycated proteins cross-link further into advanced glycation end products (AGEs). AGEs do three things that matter clinically:
They stiffen
They stiffen the matrix proteins they cross-link. Stiffer arteries raise blood pressure independent of any other risk factor. Stiffer lens crystallins make the eye lens less flexible (presbyopia, then cataract).
They bind RAGE
They bind to a receptor called RAGE (receptor for advanced glycation end products) on endothelial cells, immune cells, and neurons. RAGE activation drives chronic low-grade inflammation, oxidative stress, and pro-thrombotic signalling. This is the molecular link between high average glucose and the clinical complications of diabetes:
They starve the small vessels
They impair microvascular blood flow specifically. Capillary basement membranes thicken. Pericyte function deteriorates. Tissue oxygen delivery drops in the small vessels feeding nerves, the retina, and the kidneys. This is why diabetic complications cluster in the tissues with the densest microvascular supply.
This is the case for early reversal.
Reversing diabetes within 6 years of diagnosis (the Newcastle-defined reversibility window) puts a hard cap on cumulative AGE exposure.
The reversal-phase implication. Glycation is reversible at the rate of protein turnover. Haemoglobin turns over in 90 to 120 days, which is why HbA1c lags glucose by approximately 3 months.
This is the case for early reversal. Reverse it at year 2, you save your eyes, kidneys, nerves, and arteries from another N years of accelerated glycation. Reverse it at year 12, you reverse the metabolic disease but the microvascular and neural damage that accumulated in those 12 years partially persists.
If you already have neuropathy
If you already have peripheral neuropathy, the protocols and supplements specific to nerve recovery (alpha-lipoic acid, B12, benfotiamine, contrast hydrotherapy, red-light therapy, the full neurovascular repair stack) are covered in detail at the diabetic neuropathy reversal page. The two pages are deliberate siblings. Glucose control is the upstream prereq for nerve repair on the neuropathy page. Nerve repair is the downstream consequence of glucose control on this page. Same biology, different entry point.
One biology · five measurement points
Metabolic syndrome reversal one biology, multiple endpoints
Metabolic syndrome is the cluster diagnosis given when at least three of five markers are elevated: large waist circumference, high triglycerides, low HDL, raised blood pressure, raised fasting glucose. Type 2 diabetes is the most severe expression of the same underlying biology. Reverse the upstream mechanism and all five markers move together, because they are not five separate diseases. They are one disease (insulin resistance plus ectopic fat plus chronic low-grade inflammation) showing up at five different measurement points.
The marker order to expect, in the same protocol that reverses diabetes.
Predictable order
The marker order to expect, in the same protocol that reverses diabetes. Waist circumference moves first (week 2 to 4, as visceral fat mobilises). Triglycerides drop next (week 4 to 8, as hepatic VLDL export quiets). Fasting glucose follows (within 7 days for the hepatic-fat component, longer for the beta-cell component). Blood pressure drops next (often weeks 4 to 12, sometimes requiring medication reduction under physician supervision). HDL rises slowest (months 3 to 12). HbA1c is the final lagging integrator and shows full effect by month 6 to 12.
The portal-vein lever explains why. Visceral fat drains through the portal vein directly to the liver. The free fatty acids and inflammatory cytokines released from visceral adipocytes hit the liver in concentrated form before reaching general circulation. The liver responds by ramping up VLDL production (raising triglycerides), reducing HDL maturation (lowering HDL), increasing gluconeogenesis (raising fasting glucose), and producing C-reactive protein and other inflammatory mediators (raising systemic inflammation). The kidney responds to insulin resistance by retaining sodium (raising blood pressure). Five markers, one upstream cause.
Metabolic syndrome reversal tracks visceral and ectopic fat clearance. Lose 10 percent of body mass through a protocol that prioritises visceral mobilisation (not steady-state caloric restriction, which clears subcutaneous fat first), and the five markers move together. Triglycerides drop. HDL rises. Fasting glucose drops. Blood pressure drops, often substantially in clients on antihypertensives. Waist circumference drops faster than total body weight, which is the easiest signal that the visceral depot is mobilising preferentially.
Same protocol, multiple endpoints, predictable order.
Type 2 diabetes remission what the criteria actually require
The 2021 international consensus on type 2 diabetes remission (Riddle et al., Diabetologia, 2021), endorsed by the ADA, the European Association for the Study of Diabetes, Diabetes UK, and the Endocrine Society, defines remission with a single sharp criterion: HbA1c below 48 mmol/mol (6.5 percent), measured at least three months after stopping all glucose-lowering pharmacotherapy, sustained over time. No looser definition is medically meaningful. No tighter definition is required.
HbA1c below 48 mmol/mol (6.5 percent)
The three-month gap matters. It exists because A1C reflects the previous 90 days of average glucose. If you stop medication on Monday and measure A1C on Friday, you are reading the medication-managed glucose, not the unmedicated glucose. Three months removes the pharmacological signal entirely.
The consensus document also distinguishes partial remission (A1C 48 to 53 mmol/mol off medication) and complete remission (A1C below 42 mmol/mol off medication, sustained 1+ years). Partial remission is real and clinically valuable. Complete remission is the durability outcome the long-term DiRECT follow-up tracks.
The consensus is silent on cause. Bariatric surgery counts. VLCD-induced weight loss counts. Pharmacotherapy-induced (GLP-1 agonist, SGLT2 inhibitor) weight loss counts after the medication is stopped and the off-medication 3-month gap is observed. Lifestyle-only counts. The criterion is the outcome, not the route.
The lab markers and their thresholds, summarised.
HbA1c:
below 48 mmol/mol (6.5 percent) for remission; below 42 mmol/mol (6.0 percent) is squarely non-diabetic; below 39 mmol/mol (5.7 percent) is squarely non-prediabetic.
Fasting plasma glucose:
below 100 mg/dL (5.6 mmol/L) is non-diabetic; 100 to 125 mg/dL is prediabetic; 126 mg/dL or above on two occasions is diabetes.
OGTT 2-hour:
below 140 mg/dL (7.8 mmol/L) is non-diabetic; 140 to 199 is prediabetic; 200 or above is diabetes.
Fasting insulin:
below 8 mU/L is generally insulin-sensitive; 8 to 15 is borderline; above 15 indicates compensatory hyperinsulinaemia.
HOMA-IR:
(fasting glucose mg/dL multiplied by fasting insulin mU/L, divided by 405). Below 1.5 is sensitive; 1.5 to 2.5 is borderline; above 2.5 is resistant.
Remission is not relapse-proof. The 2-year DiRECT data showed approximately 36 percent of original intervention participants in remission. The 5-year follow-up showed approximately 11 percent. The decline is not failure of the protocol. It is regression to the underlying biology when weight regain returns. Remission re-induction is possible (Counterpoint participants who relapsed and re-entered protocol re-achieved remission in many cases), but each cycle of weight loss and regain accumulates background damage from the higher-glucose periods. The early-intervention case (reverse it within the first 6 years post-diagnosis, hold the weight loss, accept that this is now a permanent maintenance commitment) is the case that holds up in long-term data.
The carb-counting trap and why insulin-load timing beats counting
Standard diabetes guidance prescribes carb counting: track carbohydrate grams per meal, match insulin dosing or glucose response to the count. This works well for type 1 diabetics on basal-bolus insulin who need to dose-match meals. For type 2 reversal, it is the wrong tool. The trap is subtle, so it is worth naming clearly.
30 g
+40 mg/dL
30 g
+15 mg/dL
The variable is not the carbs. The variable is the metabolic state of the person eating them.
Carb counting treats glucose as the only variable. If you ate 30 g of carbs and glucose rose 40 mg/dL, the count tells you the carbs caused the rise. The count cannot tell you that the rise happened because insulin sensitivity is low and beta-cell first-phase response is impaired. The same 30 g eaten by an insulin-sensitive person produces a 15 mg/dL rise. Same carbs, different glucose.
This matters because the lever that fixes the metabolic state is not eating fewer carbs forever. It is reversing the underlying biology so that more carbs become tolerable again. The reversal protocol uses lower carb intake as a tactical lever during the deficit phase to keep insulin low and accelerate ectopic-fat clearance. Once liver and pancreatic fat normalise and beta-cell first-phase response returns, the same carb load that previously caused a 40 mg/dL rise causes a 15 mg/dL rise. The number of grams did not change. The biology underneath did.
What to track instead, in priority order:
Insulin-load timing. Heavier carb intake on training days, lower carb intake on rest days, with the largest meal at the end of the training window. This compresses average insulin exposure across the 24-hour cycle and pairs higher glucose load with the moment of highest insulin sensitivity (post-exercise GLUT4 translocation, lasting ~12-24 hours).
Carbohydrate quality, not quantity. Whole-food, intact-fibre, slow-digesting carbohydrate (lentils, oats, quinoa, whole fruit, sweet potato) produces a different glucose curve than the same gram count of refined carbohydrate. The carb-counting protocol cannot see this difference. Postprandial glucose monitoring can.
Postprandial glucose response. Fingerstick glucose at 1 hour and 2 hours post-meal tells you how your biology responded to that meal. Continuous glucose monitoring (CGM) makes this easier and reveals patterns invisible to single timepoints. The reversal protocol shifts the postprandial curve over months. Tracking the curve directly tells you the protocol is working.
None of this means carb count is irrelevant. It means carb count is a downstream proxy for what we actually care about (insulin response, beta-cell function, glycaemic stability), and there are better proxies. Use carb timing during the reversal phase, postprandial glucose response during maintenance, and stop tracking grams as soon as the underlying biology is moving in the right direction. The clients who hold remission past year three usually report they stopped counting carbs entirely by month 6 because the postprandial response normalised and the carb count became uninformative.
Why food-list dieting fails and what to do instead
The standard diabetic-diet content on the consumer web is structured as food lists: best foods for diabetics, worst foods for diabetics, the diabetic diet food list, the prediabetic shopping list. Some lists are sensible. Most are arbitrary. All of them share a structural problem: they treat food as a categorical signal ("good" or "bad"), when the reversal lever is metabolic state, dose, timing, and total energy balance.
Three reasons food-list dieting underperforms for type 2 reversal:
The same food has different effects depending on the metabolic state of the eater. Banana, white rice, oats, sweet potato, even glucose itself produces different glycaemic curves in insulin-sensitive vs insulin-resistant subjects (Wolever et al., across many GI studies). The food-list approach assigns these foods a fixed category. The reality is the assignment depends on the metabolic state the list is supposed to be helping the reader change.
Fixed lists become identity rules, not reversible interventions. Once you have decided rice is "bad," the option of eating rice in a different metabolic state never gets revisited. This is bad for compliance (binary rules fail more often than dose-based rules) and bad for clinical reality (insulin-sensitive remitters tolerate carbs that insulin-resistant pre-protocol selves did not).
Food lists conflate processing, glycaemic load, and total dose. "Avoid white bread" is a useful instruction for a reader currently eating it twice a day. It is uninformative for a reader who eats it twice a year. The list cannot see the difference. The reader treats both situations as equivalent.
What to do instead.
Replace categorical food lists with three rules of thumb:
Whole-food protein at every meal (minimum 25 to 30 g for an adult). This stabilises postprandial glucose, supports muscle preservation during weight loss, and raises satiety enough to make the energy-deficit phase tolerable.
Intact-fibre carbohydrate, dose-matched to activity. On training days, more. On rest days, less. The reversal phase runs lower across the board.
Most of your daily calories in your eating window, not spread across 5-6 small meals. Frequent eating keeps insulin elevated. The Twin Cycle reverses faster with longer fasting windows between meals.
This is three pieces of guidance. It is not 47 items on a Yes list and 38 items on a No list. It is also more accurate.
The Mediterranean dietary pattern is closer to right than to wrong on food category, and the trial evidence supports it (PREDIMED, multiple T2 prevention trials). But what the Mediterranean pattern actually does for type 2 reversal is provide a default eating context that makes the upstream levers (insulin-load timing, energy deficit, intact-fibre carbohydrate, whole-food protein) easier to follow than a Western fast-food default would. The food category matters less than the structure of meals and the relationship between meals and movement. That structural framing is the alternative to a food list.
Exercise for diabetics what works, what to skip, and what to modify
The diabetes exercise literature is unusually clear. Three modalities have strong evidence for reversing or improving the underlying biology, and they are not interchangeable. Each one moves a different mechanism.
Resistance training drives GLUT4 translocation.
Skeletal muscle has GLUT4 transporters in vesicles inside the cell. Two stimuli mobilise them to the cell membrane: insulin signalling, and muscle contraction. Resistance training (heavy compound lifts, working close to fatigue, 2-3 sessions per week) drives the contraction-mediated pathway, which is independent of insulin. This is why diabetic clients with persistent insulin resistance can still pull glucose out of circulation aggressively after a resistance session: the muscle is taking glucose without needing the broken insulin signal. The post-session insulin sensitivity boost lasts ~12-24 hours. Train every other day and the boost is essentially continuous.
Walking drives mitochondrial density and basal insulin sensitivity.
Brisk walking 30+ minutes daily (or equivalent zone-2 cardio) raises the number and quality of mitochondria in skeletal muscle. More mitochondria means more capacity to oxidise the fatty acids and glucose flowing through. The DPP trial used 150 minutes per week as the threshold and produced a 58 percent reduction in T2 conversion. The trial floor (150 min/week) is the floor, not the target. Most clients who achieve durable remission move significantly more than that.
HIIT amplifies the catecholamine cascade.
Short, intense intervals (20 seconds to 4 minutes hard, with recovery) drive adrenaline and noradrenaline higher than steady-state cardio does. The catecholamine spike opens lipolysis, lifts alpha-2 receptor inhibition on stubborn depots, and recruits Type II muscle fibres that have a different glucose-handling profile from Type I aerobic fibres. For diabetic users, HIIT requires modifications: avoid HIIT on days with active hypoglycaemia risk (sulfonylurea or insulin dosing close to the session), monitor glucose before and after, do not run HIIT in a fasted state during the early ramp of the LION protocol.
What to skip: exclusive cardio. Long, steady-state aerobic-only training without a resistance component does the least for diabetes reversal of any movement modality. It burns calories during the session but does not drive GLUT4 translocation, mitochondrial density, or catecholamine adaptation as effectively as the combined-modalities approach. If you only have time for one type of training, resistance training plus walking beats cardio-only by every relevant biomarker.
If you have peripheral neuropathy: foot-safe modifications matter.
Reduced foot sensation creates a real injury risk during high-impact training. Walk on smooth surfaces, inspect feet before and after every session, choose well-fitted athletic shoes with good shock absorption, and consider non-weight-bearing alternatives (stationary cycling, swimming, rowing) for higher-intensity work. Detailed neuropathy-specific exercise modifications are covered at the diabetic neuropathy reversal page.
This section is informational. Medication taper must be physician-directed. Stopping or reducing glucose-lowering medication outside clinical supervision can cause hypoglycaemia (sulfonylureas, insulin), rebound hyperglycaemia, or, with SGLT2 inhibitors during fasting, euglycaemic diabetic ketoacidosis. The framework below describes what physician-supervised taper typically looks like in clients who achieve sustained glycaemic improvement on the lifestyle protocol. Take it to your clinician. Do not run it solo.
How to safely taper diabetes medications and what readiness looks like
The general clinical principle: medications come off in reverse order of their hypoglycaemia risk. Once the lifestyle protocol is producing stable glucose readings without medication assistance, the medications that contributed least to glycaemic control come off first. The medications that carry the most risk if continued at full dose against improving sensitivity come off most carefully.
Typical taper readiness markers (the criteria your clinician is likely evaluating):
HbA1c below 6.0 percent on two consecutive measurements, 3 months apart, on the current regimen.
Fasting plasma glucose consistently below 100 mg/dL over 4-6 weeks of self-monitoring.
No symptomatic hypoglycaemia on the current regimen.
Stable weight at or below the post-reversal target for 3+ months (no rebound regain).
Stable lifestyle adherence: the protocol you used to reverse is the protocol you continue. Tapering medications then rebounding off the lifestyle is the most common path back to active diabetes.
Typical taper sequence (physician-directed):
SGLT2 inhibitors
(empagliflozin, dapagliflozin) often come off first if fasting protocols are part of the lifestyle approach, because of euglycaemic DKA risk during prolonged fasting.
Sulfonylureas
(gliclazide, glipizide, glimepiride) come off second or in parallel because of hypoglycaemia risk as insulin sensitivity improves.
Short-acting insulin
(around meals) comes off as postprandial response normalises.
Long-acting insulin
(basal) comes off as fasting glucose normalises.
GLP-1 agonists
are often kept longer because they produce satiety benefit beyond glycaemic control and have favourable cardiovascular and renal effects.
Metformin
is often the last to come off, or sometimes kept indefinitely. It has favourable longevity, AMPK-activating, and cardiovascular signal independent of glycaemic effect, and the hypoglycaemia risk is essentially zero.
The remission criterion (per the 2021 international consensus) requires off-medication HbA1c below 48 mmol/mol sustained 3+ months. This is why the taper sequence matters: medications must be off long enough for the A1C measurement to be a true off-medication reading, not a residual pharmacological effect. Most clinicians measure A1C 3 months after the final medication is stopped to confirm the remission threshold is met without pharmacological assistance.
Sex and age modifiers
The biology that drives type 2 diabetes is the same across sex and age. The protocol that reverses it is the same in shape, but the implementation modifies meaningfully. Most consumer reversal coverage skips this. The patterns we have observed across diabetic clients are consistent enough to name explicitly.
Female-specific modifiers
Cycle-glucose interaction. Insulin sensitivity dips in the luteal phase (post-ovulation, days 15-28 of a typical 28-day cycle) and recovers in the follicular phase. Postprandial glucose spikes can be 10-20 percent higher in luteal-phase days even on the same diet. Track across at least one full cycle before judging whether the protocol is failing.
Pregnancy and gestational priors. A history of gestational diabetes is a strong risk factor for type 2 within 5-10 years post-partum. The Twin Cycle mechanism is the same. Reversibility is high if intervention happens before the postpartum decade closes.
Perimenopause and menopause. Oestrogen decline shifts fat distribution toward visceral storage, raises insulin resistance, and accelerates the personal-fat-threshold trajectory. Many female clients first present with prediabetes or new T2 in this window. The reversal protocol still works, but expect slower visceral mobilisation and longer time to A1C normalisation.
Male-specific modifiers
Visceral-first fat distribution. Men typically deposit fat viscerally before subcutaneously. This is good news for reversal protocol response (visceral fat mobilises preferentially under low-insulin conditions), but it also means insulin resistance and ectopic-fat consequences appear at lower BMI than the population averages suggest. A male client at BMI 26 can be in active T2 reversal territory; the same female client at BMI 26 is often still in subcutaneous-storage territory.
Testosterone and insulin sensitivity. Low testosterone (common with high visceral adiposity) compounds insulin resistance. Reversing the visceral fat tends to raise testosterone moderately as part of the same protocol. See our testosterone page for the mechanism.
40s and 50s: momentum window
Most prediabetic and newly-diagnosed type 2 clients in their 40s and 50s are inside the 6-year reversibility window Roy Taylor's group identified. Beta-cell mass is still recoverable. Microvascular damage is still partly reversible. The lifestyle protocol holds well in this age band because muscle mass, recovery capacity, and metabolic flexibility are all near-baseline. This is the window where reversal has the highest ceiling and the longest durability runway.
60+ : reversibility-window urgency, modified intensity
In the 60+ band, two competing factors operate. The reversibility window may be narrowing if diagnosis was years ago, which raises urgency. At the same time, recovery capacity, sarcopenia risk, and medication interactions all complicate the protocol. Resistance training is even more important here (sarcopenia accelerates insulin resistance), but intensity ramps slower. The DPP trial showed lifestyle intervention worked dramatically better than metformin in participants over 60. The data favours the lifestyle approach in this age band, but the protocol is best run with closer clinician involvement than for younger clients.
Lab markers to track and how often
The reversal protocol changes glucose handling on multiple timescales. Different markers move on different clocks. Tracking the wrong marker on the wrong cadence produces the impression of a stalled protocol when the protocol is actually working. The cadence below is what we run with diabetic clients.
Fasting glucose (fingerstick or CGM)
Daily during reversal phase, weekly in maintenance
Hepatic insulin resistance / liver-fat clearance signal. Moves first (within 7 days).
Postprandial glucose at 1 hr and 2 hr
2-3 times per week during reversal, occasional in maintenance
Beta-cell first-phase insulin response recovery. Improves through weeks 4-12.
HbA1c
Every 3 months
90-day average glucose, lagging integrator. Do not measure more often than quarterly during the reversal phase; the value lags the protocol.
Fasting insulin and HOMA-IR
Every 3 to 6 months
Upstream insulin-sensitivity marker. Moves before A1C does. The early signal that the protocol is working.
Liver enzymes (ALT, AST, GGT)
Every 6 to 12 months
Indirect marker for liver fat clearance. ALT typically falls 30-50 percent within 12 weeks of effective protocol.
Lipid panel (TG, HDL, LDL)
Every 6 to 12 months
Triglycerides drop with hepatic VLDL export normalising. HDL rises slowest.
Waist circumference
Weekly during reversal
Fastest-moving signal that visceral depot is mobilising. Often outpaces total weight loss.
Body weight
Weekly
Confirms energy deficit. Not the upstream lever; do not optimise for it directly.
Blood pressure
Weekly
Drops alongside visceral mobilisation. Often requires antihypertensive reduction under physician supervision.
For full lab interpretation guidance across the BellyProof framework, see our blood panel decoder. The decoder covers what each marker means, what the reference ranges are, and how the BellyProof biology framing reads them differently from standard "normal range" interpretation.
Realistic timelines and what failure looks like
The honest version of type 2 diabetes reversal is shaped like a long-tail distribution. Most people see meaningful improvement. Roughly half achieve the full remission criterion. About one-third hold remission past 2 years. About 11 percent hold it past 5 years.
Beyond approximately 6 kg of regain, ectopic fat starts repacking into liver and pancreas in the same order it cleared. The Twin Cycle re-establishes.
The mechanism does not fail. Adherence does, slowly, in ways that are predictable and partially preventable.
What separates 5-year remitters from relapsers, in our work with diabetic clients:
Weight maintenance held within 6 kg of post-reversal baseline.
Lifestyle continuity, not lifestyle perfection.
The clients who hold remission did not run the reversal protocol forever. They moved to a sustainable maintenance version (insulin-load timing, training, adequate sleep) and stayed on it. The clients who relapsed mostly stopped the maintenance protocol entirely after a few months and reverted to pre-reversal habits.
An exit ramp from the VLCD phase.
The reversal-phase VLCD is not the maintenance protocol. Clients who tried to compress the protocol into a single intensive intervention (no maintenance phase, return to pre-reversal eating after VLCD) almost universally regained weight and lost remission within 18 months. Clients with a planned 6-month maintenance phase ramping out of VLCD held remission far longer.
Annual lab cadence and clinician check-in.
Quiet drift back into prediabetes is invisible without quarterly fingersticks and annual A1C. Clients who kept the cadence caught early backslide and corrected. Clients who stopped tracking only noticed when symptoms returned, by which point a re-induction protocol was needed.
What failure looks like, honestly: regain weight back toward pre-reversal baseline, fasting glucose drifts up first, A1C follows over the next 90 days, prediabetic range first, then T2 again, often within 18-30 months. The biology is symmetrical. The Twin Cycle reverses if you reverse the input, and re-establishes if you re-establish the input. None of this means the original reversal was wasted. It means the maintenance phase is the actual long-term project, and the reversal phase was just the door into it.
For most diabetic clients, the right framing is not "can I reverse my diabetes?" but "am I willing to commit to a long-term metabolic-health practice, of which reversal is the first six to twelve months?" That framing changes the protocol design. It also changes the clients who succeed.
Where to go from here. If you want to see what the cortisol-then-fat-loss-then-maintenance sequence produces in real members over the 12-24 month window, our see what members have achieved page documents diabetic-client outcomes alongside non-diabetic ones. The full coached version of the Twin Cycle reversal protocol with weekly check-ins and lab-marker tracking lives inside the BellyProof program, and if you are ready to apply this with structured guidance you can start your BellyProof journey from there.
Frequently asked questions
Can type 2 diabetes really be reversed naturally?
Is type 2 diabetes reversible?
How do I lower my A1C naturally?
What is the difference between remission and reversal of diabetes?
How long does it take to reverse type 2 diabetes?
What is the Newcastle Diet?
How does Roy Taylor's twin-cycle hypothesis explain type 2 diabetes?
Can I reverse insulin resistance?
Does intermittent fasting help with type 2 diabetes?
Can lean people get type 2 diabetes?
How many carbs should I eat per day to reverse diabetes?
How do I safely come off diabetes medications?
- Can diabetes be reversed?
- Is type 2 diabetes reversible?
- Can I reverse type 2 diabetes?
- Can you reverse type 2 diabetes? Can you reverse type two diabetes? Can you reverse diabetes 2?
- How to reverse type 2 diabetes naturally:
Three of the most common questions readers arrive with each frame the reversal question slightly differently. The answers are aligned but the framing matters because clients often arrive having read different things in different places.
Can diabetes be reversed? Yes, type 2 diabetes can be reversed in many cases. The DiRECT trial (Lean et al., Lancet, 2018) demonstrated 46 percent remission at 12 months in primary-care-delivered protocol. Type 1 diabetes cannot be reversed because beta cells have been destroyed autoimmunely; the protocols on this page do not apply to type 1.
Is type 2 diabetes reversible? Yes, type 2 diabetes is reversible in many people, particularly within the first 6 years of diagnosis. Roy Taylor's twin-cycle work showed that beta-cell function and pancreatic morphology are recoverable in this window. After approximately 10-12 years of untreated or poorly-controlled diabetes, beta-cell mass loss may exceed the recovery capacity, and remission rates drop. Earlier intervention, higher remission probability.
Can I reverse type 2 diabetes? The answer to "can I reverse type 2 diabetes" depends on three factors visible in your own labs and history: time since diagnosis (under 6 years is highest probability), baseline HbA1c (lower starting point predicts higher remission rate), and weight loss achievable and sustainable (10 to 15 percent body mass is the trial-validated threshold for higher-BMI participants; 6.5 percent for ReTUNE lean-T2 participants). If those three align favourably, the probability of reversed type 2 diabetes within 12 months of disciplined protocol adherence is meaningful, around 35 to 50 percent based on trial data.
Can you reverse type 2 diabetes? Can you reverse type two diabetes? Can you reverse diabetes 2? All three phrasings ask the same question. The mechanism applies the same way regardless of how the question is worded: clear ectopic fat from liver and pancreas in sequence, restart insulin secretion, restore insulin sensitivity in muscle and liver, sustain the weight loss long enough for beta-cell mass to rebuild. The protocols on this page are how that mechanism gets triggered. The clinician relationship is how it gets monitored safely.
How to reverse type 2 diabetes naturally: the 5-lever protocol described above (energy deficit clearing ectopic fat, low-carb cycling, LION-protocol intermittent fasting with diabetic safety modifications, resistance training plus walking, sleep architecture and stress regulation) is the consolidated answer. Run them in priority order, sustain past the reversal phase into long-term maintenance, and the durability data from DiRECT 5-year follow-up applies.
Type 2 reversal in one paragraph.
Energy deficit clears liver fat (week 1) and pancreatic fat (weeks 1-8). Beta cells de-differentiate then re-differentiate (months). Insulin sensitivity returns in muscle and liver. HbA1c lags glucose by 90 days. Remission means HbA1c below 6.5 percent off medication for at least 6 months. Durability past 5 years tracks weight maintenance. The mechanism is symmetric: the cycles reverse if you reverse the input, and re-establish if you re-establish it.
The shorter answers, summarised:
Is diabetes reversible? Type 2 diabetes is reversible in many people; type 1 is not. The question "is diabetes reversible" is answered yes for type 2 within the early-diagnosis window. Reversed type 2 diabetes is the same medical state as type 2 diabetes remission per the 2021 international consensus, and the durability tracking from DiRECT 5-year follow-up applies to anyone with reversed type 2 diabetes status. Visceral fat and diabetes are linked through portal-vein delivery of free fatty acids and inflammatory mediators directly to the liver, which is the upstream lesion in the twin-cycle hypothesis described above. The visceral fat and diabetes connection is also why waist circumference moves earlier and faster than total body weight during the reversal phase, and the visceral fat and diabetes link directly drives the metabolic-syndrome cluster as well. Visceral fat insulin resistance is the localised expression of that mechanism inside the abdominal depot, and visceral fat insulin resistance precedes muscular and hepatic insulin resistance in most type 2 trajectories. Insulin resistance reversal follows the same five-lever protocol that reverses diabetes itself, with HOMA-IR moving first and HbA1c following on the 90-day clock. The phrase "insulin resistance reversal" is interchangeable with the early-stage version of the diabetes-reversal protocol on this page. Remission of type 2 diabetes is achievable in approximately 46 percent of structured-protocol participants at 12 months (DiRECT), with one-third holding remission of type 2 diabetes at 2 years and approximately 11 percent at 5 years. Fasting and diabetes together require physician supervision when glucose-lowering medications are involved; the LION-protocol-for-diabetics section above names the specific guardrails for combining fasting and diabetes safely. How to lower blood sugar naturally reduces to the same five-lever protocol consolidated in this guide; "how to lower blood sugar naturally" is upstream of the broader reversal question and is achievable earlier in the metabolic continuum.
Phrasing variants of the same question: readers ask can you reverse type 2 diabetes, can you reverse type 2, can you reverse type two diabetes, and can you reverse diabetes 2 across different searches. All four ask the same thing, and the answer is the same. Yes, in many cases, with the qualifications described throughout this guide regarding time since diagnosis, weight-loss target, and durability dependence on long-term weight maintenance. So can you reverse type 2 diabetes? In the right window, with the right protocol, sustained over the right timescale, often yes. Can you reverse type 2 in lean people with TOFI presentation? ReTUNE 2023 says yes. Can you reverse type two diabetes after 15 years of progression and severe beta-cell mass loss? The probability drops; partial improvement is still achievable. Can you reverse diabetes 2 after type 1 was misdiagnosed as type 2? No, because the underlying autoimmune destruction does not respond to the lifestyle protocol. The diagnosis matters; the protocol assumes the diagnosis is correct.
The umbrella term "insulin resistance treatment" covers a wide range of interventions, and they are not interchangeable. The right framing for this page is to separate them by mechanism. Pharmacological insulin resistance treatment (metformin, GLP-1 agonists, SGLT2 inhibitors) operates on the symptom layer and has roles in clinical care. Lifestyle insulin resistance treatment operates on the upstream cause (ectopic fat in liver, pancreas, and visceral depots) and is what produces the durable remission outcomes documented in DiRECT.
Insulin resistance diet in the BellyProof framing is not a fixed food list. It is a dietary pattern shaped by three principles: whole-food protein at every meal, intact-fibre carbohydrate dose-matched to activity, and most calories inside a defined eating window. The Mediterranean dietary pattern is the closest mainstream pattern, but the lever it pulls (reduced average insulin exposure, sustained energy deficit through whole-food satiety, anti-inflammatory polyphenol load) is the same lever the LION protocol pulls more aggressively. An insulin resistance diet that does not lower average daily insulin and energy intake will not move the underlying biology, regardless of which foods it includes or excludes.
Insulin resistance reversal follows the same biology as the broader type 2 reversal protocol because insulin resistance is the upstream lesion that defines type 2 diabetes. There is no separate insulin-resistance-reversal protocol distinct from the diabetes-reversal protocol on this page. There is one protocol that reverses both, with insulin resistance moving first (HOMA-IR drops within weeks) and HbA1c following on the 90-day red-blood-cell turnover clock. Catch insulin resistance early enough (prediabetes, metabolic syndrome, fatty liver without yet meeting diabetes diagnostic criteria) and the reversal window is wider, the protocol is gentler, and the durability is higher.
The relationship between intermittent fasting and type 2 diabetes is one of the more nuanced topics in this space. Trial data on intermittent fasting for type 2 diabetes shows meaningful HbA1c improvements in supervised settings, but practical implementation requires the diabetic safety modifications described in the LION-protocol-for-diabetics section above.
Fasting and diabetes as a topic predates intermittent-fasting branding by decades. Earlier work on prolonged medically-supervised fasting (5-7 days, water-only) showed dramatic acute improvements in fasting glucose and insulin sensitivity, with the same risks of hypoglycaemia that constrain extended fasting in clinical care today. The contemporary framing of fasting for type 2 diabetes typically means time-restricted feeding (16-18 hour overnight extension) or alternate-day modified-fasting protocols. Both work through the same upstream lever: reduce average daily insulin exposure, increase the fraction of the 24-hour cycle in which lipolysis runs, accelerate ectopic-fat clearance.
Intermittent fasting for type 2 diabetes is not a substitute for medical care. It is a tool that pairs with medication management, weight-loss intervention, and lab-tracked progress. For clients on glucose-lowering medication, intermittent fasting and type 2 diabetes coordination requires the physician relationship described above. For clients with prediabetes or insulin resistance not yet at diabetes thresholds, intermittent fasting can be a safer first lever, but the same self-monitoring discipline (fasting glucose check, hypoglycaemia awareness, gradual ramp) applies.
How many carbs per day a person with type 2 diabetes should eat is one of the most-searched questions on this topic, and the standard answers (the diabetic diet food list, the prediabetic carb-count chart, the 130 g/day general guidance) miss the deeper mechanism we walked through above. How many carbs should a diabetic have per day is the wrong framing because the answer depends on the diabetic person's metabolic state, training day vs rest day, and total energy balance, not a single universal number.
That said, here is a useful starting frame. During the reversal phase (12-16 weeks of disciplined protocol), most clients run between 50 and 100 g of carbohydrate per day, weighted heavily toward training days. This range is not a prescription; it is what the protocol's other levers tend to produce when energy deficit, low-carb cycling, and intermittent fasting are all running together. During maintenance, the carb intake typically rises to 100-200 g per day on training days and 50-100 g on rest days, again weighted by activity. The exact number drifts upward as insulin sensitivity improves; the same client at month 18 of remission tolerates significantly more carbohydrate without postprandial glucose spikes than they did at month 2.
For readers searching variants of "how many carbs per day for diabetic" or "how many carbs should a diabetic have per day," the more useful answer is the postprandial-glucose-monitoring approach: track your own 1-hour and 2-hour glucose response to specific meals over a few weeks. The number that keeps your 2-hour reading below 140 mg/dL is your number, and it changes as the protocol works.
How to lower blood sugar naturally shares the same answer set. The five-lever protocol described earlier is the consolidated response to lower-blood-sugar-naturally queries, with the additional caveat that "naturally" in this context typically means "without adding new medication." Existing medications continue under physician guidance until taper readiness criteria are met.
If you also have diabetic neuropathy
Glucose control is the upstream prereq for nerve repair. The dedicated diabetic neuropathy reversal page covers the nerve-specific protocol: alpha-lipoic acid dosing, B12 and benfotiamine, the contrast hydrotherapy and red-light protocols, and exercise modifications for neuropathic feet.
Scientific References
Type 2 Diabetes Reversal: Roy Taylor and the Newcastle Group
-
Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54(10):2506-2514. https://doi.org/10.1007/s00125-011-2204-7
Counterpoint study, n=11. 600 kcal/day for 8 weeks normalised fasting plasma glucose by week 1 and beta-cell function by week 8 in newly-diagnosed type 2 participants.
DOI (opens in new tab) -
Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and non-responders. Diabetes Care. 2016;39(5):808-815. https://doi.org/10.2337/dc15-1942
Counterbalance study. Pancreatic triacylglycerol normalised in responders alongside restored first-phase insulin response. Weight stability over 6 months held remission.
DOI (opens in new tab) -
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541-551. https://doi.org/10.1016/S0140-6736(17)33102-1
DiRECT trial 12-month results, n=298. 46 percent of intervention participants achieved diabetes remission. Remission strongly associated with magnitude of weight loss.
DOI (opens in new tab) -
Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes & Endocrinology. 2019;7(5):344-355. https://doi.org/10.1016/S2213-8587(19)30068-3
DiRECT 24-month results. One-third of original intervention group remained in remission at 2 years. Sustained remission tracked sustained weight loss.
DOI (opens in new tab) -
Hepatic lipoprotein export and remission of human type 2 diabetes after weight loss. Cell Metabolism. 2020;31(2):233-249.e4. https://doi.org/10.1016/j.cmet.2019.11.018
Hepatic VLDL-triglyceride export and pancreatic morphology trajectory across DiRECT 24-month follow-up. Beta-cell function recovery sustained at 2 years.
DOI (opens in new tab) -
Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes & Endocrinology. 2019;7(9):726-736. https://doi.org/10.1016/S2213-8587(19)30076-2
Twin-cycle hypothesis review. Liver fat to pancreatic fat to beta-cell de-differentiation, and the reversal of each step on weight loss.
DOI (opens in new tab) -
Aetiology of type 2 diabetes in people with a "normal" body mass index: testing the personal fat threshold hypothesis. Clinical Science. 2023;137(16):1333-1346. https://doi.org/10.1042/CS20230586
ReTUNE study, BMI 21-27. Mean 6.5 percent weight loss; 70 percent achieved remission. Same mechanism as DiRECT, lower starting BMI.
DOI (opens in new tab) -
Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia. 2021;64(11):2359-2366. https://doi.org/10.1007/s00125-021-05542-z
International consensus: T2 remission defined as HbA1c below 48 mmol/mol (6.5 percent), measured at least three months after stopping all glucose-lowering pharmacotherapy.
DOI (opens in new tab) -
Life Without Diabetes: The definitive guide to understanding and reversing type 2 diabetes. Short Books, 2020. ISBN 978-1780724874.
Roy Taylor consumer-facing book translating the twin-cycle hypothesis and Newcastle Diet protocol for general readers.
Insulin Resistance, Lifestyle Intervention, and Glucose Metabolism
-
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346(6):393-403. https://doi.org/10.1056/NEJMoa012512
DPP trial. Lifestyle intervention with 7 percent weight loss and 150 minutes per week activity reduced T2 conversion by 58 percent in prediabetic adults; metformin reduced by 31 percent.
DOI (opens in new tab) -
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-1686. https://doi.org/10.1016/S0140-6736(09)61457-4
DPPOS 10-year follow-up. Lifestyle intervention benefit persisted at 10 years; T2 incidence reduced by 34 percent vs placebo.
DOI (opens in new tab) -
A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. Journal of Clinical Endocrinology & Metabolism. 2010;95(6):2963-2968. https://pubmed.ncbi.nlm.nih.gov/20371664/
In healthy adults, one night of 4-hour sleep vs normal ~7.5-hour night. Under hyperinsulinemic-euglycemic clamp the next morning, endogenous glucose production rose 4.4 vs 3.6 micromol/kg/min (~22% impaired hepatic suppression) and peripheral glucose disposal fell 32.5 vs 40.7 micromol/kg/min (~20% reduction in muscle/peripheral uptake). Different tissues, different magnitudes; both pathways affected after a single short-sleep night.
PubMed (opens in new tab) -
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. https://doi.org/10.1007/BF00280883
Original HOMA-IR formula. (Fasting glucose mg/dL multiplied by fasting insulin mU/L, divided by 405).
DOI (opens in new tab) -
Exercise-induced increase in muscle insulin sensitivity. Journal of Applied Physiology. 2005;99(1):338-343. https://doi.org/10.1152/japplphysiol.00123.2005
Exercise-induced GLUT4 translocation: muscle contraction triggers glucose uptake through an insulin-independent pathway.
DOI (opens in new tab)
Glycation, Advanced Glycation End Products (AGEs), and Microvascular Damage
-
The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615-1625. https://doi.org/10.2337/diabetes.54.6.1615
Unifying mechanism for diabetic complications: hyperglycaemia drives advanced glycation end product formation, RAGE activation, and microvascular damage.
DOI (opens in new tab) -
Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129-146. https://doi.org/10.1007/s001250051591
AGE formation kinetics in long-lived proteins. Collagen cross-linking and tissue stiffening.
DOI (opens in new tab) -
Receptor for AGE (RAGE) and its ligands - cast into leading roles in diabetes and the inflammatory response. Journal of Molecular Medicine. 2009;87(3):235-247. https://doi.org/10.1007/s00109-009-0439-2
RAGE activation drives chronic inflammation, oxidative stress, and pro-thrombotic signalling. Molecular link between high glucose and diabetic complications.
DOI (opens in new tab)
Visceral Fat, Portal Vein Biology, and Metabolic Syndrome
-
Visceral fat and metabolic inflammation: the portal theory revisited. Obesity Reviews. 2012;13 Suppl 2:30-39. https://doi.org/10.1111/j.1467-789X.2012.01035.x
Portal vein delivers visceral adipose-derived free fatty acids and inflammatory mediators directly to the liver, driving hepatic insulin resistance.
DOI (opens in new tab) -
Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881-887. https://doi.org/10.1038/nature05488
Visceral adiposity is the upstream lesion in metabolic syndrome. Triglyceride elevation, HDL reduction, and insulin resistance are downstream consequences.
DOI (opens in new tab) -
Pathophysiology of human visceral obesity: an update. Physiological Reviews. 2013;93(1):359-404. https://doi.org/10.1152/physrev.00033.2011
Visceral fat accumulation drives hepatic VLDL export, dyslipidaemia, hypertension, and insulin resistance through the portal-vein route.
DOI (opens in new tab)
Mediterranean Diet and Type 2 Diabetes Prevention
-
Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. New England Journal of Medicine. 2018;378(25):e34. https://doi.org/10.1056/NEJMoa1800389
PREDIMED trial. Mediterranean dietary pattern reduced major cardiovascular events by approximately 30 percent vs control diet over 5 years in high-risk adults.
DOI (opens in new tab) -
Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomised trial. Annals of Internal Medicine. 2014;160(1):1-10. https://doi.org/10.7326/M13-1725
PREDIMED diabetes-prevention subgroup analysis. Mediterranean diet reduced T2 incidence by 30-52 percent vs control diet.
DOI (opens in new tab)
Sex, Age, and Hormonal Modifiers of Glucose Metabolism
-
Longitudinal study of insulin resistance and sex hormones over the menstrual cycle: the BioCycle Study. Journal of Clinical Endocrinology & Metabolism. 2010;95(12):5435-5442. https://doi.org/10.1210/jc.2010-0702
Insulin sensitivity varies across the menstrual cycle, with reduced sensitivity in the luteal phase. Cycle-glucose interaction documented in healthy premenopausal women.
DOI (opens in new tab) -
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373(9677):1773-1779. https://doi.org/10.1016/S0140-6736(09)60731-5
Women with prior gestational diabetes have approximately seven-fold increased risk of subsequent type 2 diabetes within 5-10 years post-partum.
DOI (opens in new tab) -
Sex differences in the metabolic syndrome: implications for cardiovascular health in women. Clinical Chemistry. 2014;60(1):44-52. https://doi.org/10.1373/clinchem.2013.202549
Sex differences in metabolic syndrome presentation and progression. Perimenopausal shift toward visceral adiposity and rising insulin resistance.
DOI (opens in new tab)
